Welcome to our dedicated page for Mangoceuticals news (Ticker: MGRX), a resource for investors and traders seeking the latest updates and insights on Mangoceuticals stock.
Mangoceuticals, Inc. develops, markets and sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands. Company news commonly covers telehealth programs for erectile dysfunction, hair growth, hormone replacement therapy and weight management, including prescription access and fulfillment through pharmacy partners when medically appropriate.
Recurring updates also include product and intellectual-property developments such as MGX-0024, an antiviral animal feed and drinking water additive technology, as well as capital actions, platform operations and legal matters involving technology vendors. The company’s releases often connect its wellness brands, digital consultation model and eCommerce infrastructure to new treatment categories and operating initiatives.
Mangoceuticals (NASDAQ:MGRX) reported that its merger partner Nuclea Energy, through subsidiary Nuclea Energy Canada, has signed a definitive agreement to acquire advanced nuclear technology assets from Moltex Energy, which is currently in administration. The asset deal covers intellectual property and development materials for Moltex’s SSR‑W advanced molten salt reactor, the WATSS spent-fuel recycling process, the FLEX reactor concept, and an extensive portfolio of around 80 patents across nine patent families plus nine pending patents.
According to Nuclea, the portfolio reflects over a decade of R&D supported by more than C$96 million in combined private and public funding from Canadian and U.S. government programs and investors. The purchase price will be paid entirely in cash by Nuclea Energy Canada, subject to a downward adjustment for certain external debts and exclusive of value-added tax.
The technologies remain in development and are not yet commercial, with further engineering, regulatory work, testing and capital required. Completion of the transaction is subject to multiple closing conditions, including review under the UK National Security and Investment Act, and assets are being acquired on an “as is” basis with limited warranties.
The announcement follows Mangoceuticals and Nuclea’s July 30, 2026 definitive business combination agreement, which is intended to provide Nuclea a route to a Nasdaq listing and broader access to capital to advance its Morpheus microreactor, Moltex-derived reactor designs, and WATSS fuel-recycling technology, subject to shareholder and regulatory approvals.
Mangoceuticals (NASDAQ: MGRX) reported that its merger partner, Nuclea Energy, signed a non-binding MOU with New Mining Co. to study deploying Nuclea’s modular reactor technology as behind-the-meter power for New Mining’s high-density computing and Bitcoin mining operations.
The parties will first assess engineering for roughly 30 MWe of existing data center load, then evaluate scalable expansion toward up to 100 MWe/b) of cumulative capacity. Nuclea will provide technical advisory, reactor design specifications, microgrid integration planning, and preliminary regulatory and zoning strategy, while New Mining supplies site, engineering and power-usage data. The MOU does not create any power supply or offtake commitment, and any future generation would be operated by a separate qualified utility or nuclear operator. Mangoceuticals highlighted this MOU as reinforcing the strategic rationale for the definitive business combination agreement with Nuclea, which is intended to give Nuclea a path to a Nasdaq listing, subject to customary shareholder and regulatory approvals.
Mangoceuticals (NASDAQ: MGRX) reported that its merger partner’s subsidiary, Nuclea Energy USA, signed a memorandum of understanding with the Utah Office of Energy Development (OED) to explore siting a nuclear test reactor at the Utah San Rafael Energy Lab (USREL) for the Morpheus microreactor.
The MOU supports evaluation of a test reactor site, coordination with the U.S. Department of Energy and Nuclear Regulatory Commission, and assessment of future deployment pathways for Nuclea’s lead‑cooled, graphite‑moderated micro‑modular reactor in Utah. According to Mangoceuticals, this progress underscores the strategic rationale for the July 30, 2026 definitive business combination agreement with Nuclea, which is intended to provide Nuclea a path to a Nasdaq listing and broader capital access. Completion of the merger remains subject to customary stockholder and regulatory approvals.
Mangoceuticals (NASDAQ: MGRX) received a 180-day Nasdaq extension to regain compliance with the $1.00 minimum bid price under Listing Rule 5550(a)(2). The company now has until February 1, 2027 for its stock to close at or above $1.00 for at least 10 consecutive business days.
Nasdaq granted the extension after Mangoceuticals met other listing and market value requirements and provided written notice that it may use a reverse stock split, if needed. The company also continues to advance its definitive business combination agreement with Nuclea Energy, which is developing the Morpheus lead‑cooled micro modular reactor.
Mangoceuticals (NASDAQ: MGRX) has signed a definitive business combination agreement with Nuclea Energy, a Canadian advanced nuclear developer of the lead-cooled Morpheus microreactor, currently at conceptual design and targeting 3.5–50 MWe output.
A newly formed Mangoceuticals subsidiary will amalgamate with Nuclea, and the combined entity will continue as an indirect wholly owned Mangoceuticals subsidiary. Nuclea shareholders will receive exchangeable shares in a Mangoceuticals subsidiary, exchangeable one-for-one into Mangoceuticals common stock with intended equivalent economic and voting rights, but initially restricted by a Nasdaq Cap limiting aggregate economic, voting and exchange rights to 19.99% of Mangoceuticals’ pre-closing outstanding shares until both stockholder approval and Nasdaq initial listing approval are obtained. The deal, approved by both companies’ boards, is intended to give Nuclea a Nasdaq listing and provide Mangoceuticals shareholders exposure to the advanced nuclear and AI-driven power market. Following the initial closing, Mangoceuticals plans to file a Form S-4 with the SEC, including a proxy statement to seek stockholder approval for issuances above the Nasdaq Cap.
Summary not available.
Mangoceuticals (NASDAQ: MGRX) filed a PCT international application (P-641039-PC) on February 26, 2026 to seek global patent protection for its antiviral animal feed and drinking water additive technology that powers MGX-0024.
The filing claims priority to U.S. provisional 63/763,785 (Feb 26, 2025), extends protection to 150+ countries, and cites zero respiratory mortality in 29,000 commercial birds plus significant prophylactic benefit versus H5N1 in a controlled challenge study. U.S. protection remains under Patent No. 11,517,523 with national patents granted or pending in major jurisdictions.
Mangoceuticals (NASDAQ: MGRX) reported that its antiviral MGX-0024 produced zero respiratory-related mortality across approximately 29,000 treated broiler chickens in three independent commercial field trials, versus an expected ~50% (≈14,500) respiratory mortality in untreated historical/comparator flocks. A controlled BSL-3 H5N1 challenge showed up to 60% mortality reduction (2/7 vs 5/7) and extended mean time-to-death to 10.71 days from 5.86 days. MGX-0024 is a GRAS-classified polyphenol-plus-zinc formulation, covered by U.S. Patent No. 11,517,523 and corresponding international patents. Company emphasizes further validation, larger field trials, and regulatory engagement before any approved veterinary use.
Mangoceuticals (NASDAQ: MGRX) reported early traction for a newly launched all-inclusive injectable Testosterone Replacement Therapy (TRT) program priced at $99/month. MangoRx cites 336% month-over-month sales growth since mid-December and a 54% reduction in customer acquisition cost.
The offer includes doctor visits, labs, and prescribed medication. Management expects TRT to be the primary near-term growth driver while expanding telehealth men’s health services and maintaining regulatory compliance.
Mangoceuticals (NASDAQ: MGRX) closed a registered direct offering and concurrent private placement on December 19, 2025, raising approximately $2.5 million in gross proceeds.
The company sold 1,930,502 Common Units (or Pre-Funded Units) at an offering price of $1.295 per Common Unit (or $1.29499 per Pre-Funded Unit) and issued accompanying PIPE Common Warrants exercisable at $1.4245. Pre-funded warrants are immediately exercisable.
Proceeds are expected to be used for general corporate purposes and working capital. Aegis Capital acted as placement agent; the offering was made under an effective Form S-3 shelf declared effective June 24, 2025.